These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29989890)

  • 1. Trying to Sidestep Off-Label Dance-Around.
    Kirkner RM
    Manag Care; 2018 Jul; 27(7):6-7. PubMed ID: 29989890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B
    BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
    [No Abstract]   [Full Text] [Related]  

  • 3. Court rules that FDA cannot restrict off-label marketing.
    Roehr B
    BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
    [No Abstract]   [Full Text] [Related]  

  • 4. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 7. Off-label marketing: free speech or illegal promotion?
    Silverman E
    BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
    [No Abstract]   [Full Text] [Related]  

  • 8. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
    Gilhooley M
    Am J Law Med; 2011; 37(2-3):258-77. PubMed ID: 21847881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
    Sharfstein JM; Charo A
    JAMA; 2015 Nov; 314(17):1795-6. PubMed ID: 26367520
    [No Abstract]   [Full Text] [Related]  

  • 10. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 11. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
    Larkin I; Ang D; Avorn J; Kesselheim AS
    Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA regulation of off-label drug promotion under attack.
    Kesselheim AS; Mello MM; Avorn J
    JAMA; 2013 Feb; 309(5):445-6. PubMed ID: 23385267
    [No Abstract]   [Full Text] [Related]  

  • 13. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
    Bagley CE; Mitts J; Tinsley RJ
    Cornell J Law Public Policy; 2013; 23(2):337-93. PubMed ID: 25330567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hidden truth: The perils and protection of off-label drug and medical device promotion.
    Conko G
    Health Matrix Clevel; 2011; 21(1):149-87. PubMed ID: 21847900
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigating pharmaceutical marketing in Canada using American prosecutions.
    Shoucri R; Persaud N
    Int J Risk Saf Med; 2014; 26(3):147-53. PubMed ID: 25214160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 17. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 18. Lawsuit challenges FDA's authority to prevent off-label marketing.
    Dyer O
    BMJ; 2015 May; 350():h2587. PubMed ID: 25985341
    [No Abstract]   [Full Text] [Related]  

  • 19. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 20. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
    Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
    Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.